This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

March 1-3, 2021

March 1-3, 2021

A series of FREE virtual webinars to access antibody-related learning year-round

Get the the latest insights for accelerating next generation antibodies to commercial success and get answer your burning questions during the live Q&A with these industry experts

Join us March 1-3, 2021 for Antibodies, Next-Generation Proteins & Bioconjugates Digital Week, a 3-day series of live educational webinars and downloadable resources providing the latest insights for accelerating the discovery and development of antibodies, bioconjugates and next-generation protein therapeutics to commercial success. To sponsor future digital week events, contact

Engineering Bispecific Antibodies as Therapeutics: Utilizing Intrinsic Heavy/Light Chain Pairing Preferences and Mitigating High Viscosity

- Paul J. Carter, Ph.D., Genentech Fellow, Department of Antibody Engineering, Genentech

Writing the Future of Biologics using the Twist Biopharma Library of Libraries

- Aaron Sato. PhD, Chief Scientific Officer, Twist Bioscience

Quantitative Modeling and Simulation to Drive Critical Decisions from Research through Clinical Trials

- John M. Burke, PhD, Co-founder, President and CEO, Applied BioMath

Drug-like antibodies directly from selections: Specifica’s Generation 3 Antibody Library Platform

- Andrew Bradbury, Chief Scientific Officer, Specifica

Targeted C’Dot-drug Conjugates (CDCs), a Novel Nanoparticle-based Platform for the Treatment of Cancer

- Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology

Tackle Difficult Targets by Accessing Broad B Cell Diversity 

- Patricia Odermatt, MSc., Research Scientist, Single B cell Technology, Genovac Antibody Discovery 

- Anupam Singhal, PhD, Sr. Product Manager, Antibody Discovery, Berkeley Lights  

Antibody-siRNA Conjugates

- Arthur Levin, Ph.D., Chief Scientific Officer, Avidity Biosciences 

Leveraging polyclonal antibody sequencing to get high affinity binders against tough targets

- Anthony Stajduhar, Director of International Business Development, Rapid Novor Inc 

Rapid development and troubleshooting of robust microfluidic antibody-based therapeutic quantification for pharmacokinetic (PK) and toxicokinetic (TK) study support

- Rob Durham, PhD, Director of Service and Scientific Support, Gyros Protein Technologies

Why Attend a Webinar?

Time and Cost-Efficient

You will save valuable time and money because there is no need to travel and no registration fee.

Focused and Timely Learning

You will receive the latest "hot" and timely data from a leading authority


You can participate in a webinar from a location of your choosing – your home, your office, or a client/customer location